Clinical trial
A Study to Investigate LYL797 in Adults With Solid Tumors
NCT05274451
Study timeline
Study start (actual)2022-03-29Date precision: day
Registry last updated2025-07-01
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Triple Negative Breast Cancerunresolved
TNBC - Triple-Negative Breast Cancerunresolved
Non-small Cell Lung Cancerunresolved
Non Small Cell Lung Cancerunresolved
Non Small Cell Lung Cancer Metastaticunresolved
Advanced Breast Cancerunresolved
Advanced Lung Carcinomaunresolved
NSCLCunresolved
NSCLC, Recurrentunresolved
NSCLC Stage IVunresolved
Relapsed Cancerunresolved
Relapse/Recurrenceunresolved
Recurrent Breast Cancerunresolved
Recurrent NSCLCunresolved
Platinum-resistant Ovarian Cancerunresolved
Ovarian Cancerunresolved
Primary Peritoneal Carcinomaunresolved
Fallopian Tube Cancerunresolved
Endometrial Cancerunresolved
Endometrioid Tumorunresolved
High Grade Serous Carcinomaunresolved
Ovarian Epithelial Cancerunresolved
Interventions
LYL797BIOLOGICAL
Sponsors & collaborators
Lyell Immunopharma, Inc.lead sponsor
Mapped research locations
New YorkNew York, United States1HoustonTexas, United States1ChicagoIllinois, United States1PhiladelphiaPennsylvania, United States1MiamiFlorida, United States1NashvilleTennessee, United States1SeattleWashington, United States1PortlandOregon, United States1Washington D.C.District of Columbia, United States1JacksonvilleFlorida, United States1Oklahoma CityOklahoma, United States1DetroitMichigan, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT05274451 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.